Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07125209 · ClinicalTrials.gov registry record
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
A clinical trial of Ovarian Cancer and Cognitive Change, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 18
- Enrollment target
- 1
- Study location
NCT07125209: Recruiting study of Ovarian Cancer and Cognitive Change, sponsored by University of Wisconsin, Madison.
NCT07125209 is a study of Ovarian Cancer and Cognitive Change that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 18 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07125209, a study of Ovarian Cancer and Cognitive Change, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approximately 10 months.
Primary Outcome
The MMSE is a common overall test of cognition used in research and clinical settings. It is an 11 item test that assesses five domains of cognition: orientation, registration, attention, recall and language. This measure takes around 5-10 minutes to complete and is scored out of 30 with scores of 18-23 representing mild cognitive impairment and scores of 17 or less representing severe cognitive impairment.
Conditions Studied
Interventions
- OTHER Patient Reported Outcomes Assessment
- OTHER Cognitive and General Health Assessments
Study Locations (1)
Wisconsin
- UW Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-12 |
What NCT07125209 shows while recruiting
NCT07125209 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Patient Reported Outcomes Assessment is the first listed.
NCT07125209 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07125209 about?
NCT07125209 is a clinical study titled "Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer". The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approxi...
What is the current status of trial NCT07125209?
This trial is currently recruiting. The enrollment target is 18 participants. The study started on 2026-03. Estimated completion is 2027-12.
What conditions does trial NCT07125209 study?
This clinical trial studies the following conditions: Ovarian Cancer, Cognitive Change.
What interventions are being tested in trial NCT07125209?
The interventions under investigation include: Patient Reported Outcomes Assessment (OTHER), Cognitive and General Health Assessments (OTHER).
Who is sponsoring clinical trial NCT07125209?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07125209 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07125209's enrollment target sits among peer trials
18 291st of 322 higher than 26 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia